Treace Medical: The Portfolio Is Working; the P&L Is Still Catching Up

Double-digit procedure growth and a $700 million TAM expansion meet a 4% revenue decline and a narrowed guide — Q4 is the referendum.

TMCI · Earnings Call · 2026-11-06

A growth story with a revenue problem

Treace Medical came into its third-quarter report with a transition story investors have heard for a year: the company is no longer just a Lapiplasty bunion business; it is becoming a broader foot-and-ankle platform. The clinical evidence is getting stronger. The financial evidence is still awkward. Revenue fell 4% to $48.3 million, and management narrowed full-year guidance to $206 million-$210 million, lifting the low end but cutting the top end.

Revenue in the third quarter was $48.3 million a decrease of 4% compared to the prior year period. The decline was mainly driven by the shift in revenue mix towards lower priced, minimally invasive products and a lower volume of bunion procedure kits sold.
Mark L. Hair, Chief Financial Officer · 2026-11-06

The explanation matters more than the headline. Excluding sales to stocking distributors, management said bunion kit volumes increased and revenue grew mid-single digits. Procedure volume growth was double digit. That is the central tension: volume growth is real, but reported revenue is being dragged by price/mix and a one-time comparison. The phrase stocking distributor jumped to the top of Treace's keyword stack this quarter — it was not a top-30 theme before — and it does a lot of work in the story. It explains why a company gaining share and adding products can still print a down quarter.

The ASP scissors are closing, but not closed

The more persistent issue is ASP mix. Treace's newer minimally invasive bunion systems carry lower average selling prices than legacy Lapiplasty, so adoption is good for procedure volume and bad for revenue per case. John Treace was candid that this does not fully go away: “there is going to be some of that dynamic where overall ASPs or revenue per case may come down a bit from where they have historically been.” — John T. Treace, Chief Executive Officer · 2026-11-06 This was supposed to be the year the comparison eased. In May, Mark Hair said the ASP headwind would persist until the company lapped the 2025 launches: “We anticipate to continue to see that until we begin to lap or to have an anniversary of when we made these new products available, it's really in the third quarter of this year.” — Mark Hair, Chief Financial Officer · 2026-05-08 The third quarter is here, and revenue is still down 4%. Management now points to Q4 as the first clean quarter, when the company laps the mix shift and benefits from 2026 launches. The guidance move reflects that cautious setup. Treace beat Q3 by roughly $5 million, according to the analyst on the call, but did not raise the high end. Mark Hair: “Our views on Q4 are really unchanged. The magnitude of the Q3 beat, as you mentioned, is relatively modest and does not necessarily warrant a change portfolio or outlook at this stage.” — Mark L. Hair, Chief Financial Officer · 2026-11-06 That is not a demand warning, but it is not a victory lap either.

The installed base is doing the work

The bull case is not a new-customer land grab. It is penetration of the 3,300-surgeon existing customer base. Through Q3, approximately 45% of Lapiplasty surgeons used at least one of the three new bunion systems, up from 40% in Q2. In August, John Treace described the same metric moving from 35% to 40%: “We went from 35% of our 3,300 surgeon base using those products last quarter to 40%.” — John Treace, Chief Executive Officer · 2026-08-07 The curve is steady, not explosive, but it is the kind of adoption that compounds if reorder rates hold. Management says they do: “the reorder rate or the repeat customer rate when they adopt 1 of these new systems is, I can tell you, pretty high.” — John T. Treace, Chief Executive Officer · 2026-11-06 The broad portfolio is also expanding the addressable market. Treace says the 2026 product introductions — SuperByte compression screws, HyperPlate XM, Vitafuse, CartiBlaster, and the forthcoming TaylorPlasty — add roughly $700 million of U.S. TAM. More importantly, management estimates the average surgeon's reconstructive foot-and-ankle volume that Treace can serve has risen from around 30% to 80% or more. That is the strategic pivot in one sentence: from a bunion procedure to a foot-and-ankle bag.

What management stopped emphasizing

The language shift is subtle but telling. In Q1 2026, sales force was the company's No. 1 keyword. This quarter it does not appear in the top 30. Management still talks about reps, but the message has changed from expansion to leverage. John Treace said the bigger bag means reps are in 1.5x as many cases, and Mark Hair described sales additions as largely variable and incremental. After years of building a direct sales force, the emphasis is now on productivity per rep, not headcount. Cash is another theme that has moved from center stage to background. cash usage is still in the top 30, but far below its prior prominence. The balance sheet is the constraint that makes the Q4 proof point urgent. Cash, cash equivalents, and marketable securities were $39.8 million at September 30. On the fundamentals series, effective net cash was $19 million, down 76% year over year from a $258 million peak in 2023Q1. Management reiterated a roughly 50% reduction in cash usage for 2026, but the margin for error is thin. Margins are not the problem. Gross margin was 78.5% in the latest fundamentals period, down only 1.2 percentage points year over year. The problem is converting clinical adoption into dollar growth fast enough to cover the operating base. At 1.3x price to revenue, down 27% year over year, the market is not paying much for the TAM story yet.

The fourth quarter is the referendum

Treace is asking investors to judge it on the seasonally strongest quarter, when busy season bunion volumes meet a fuller product bag. The setup is plausible. But the market backdrop is not helpful. Mark Hair warned: “The foot and ankle market has historically grown mid single digits. But more recently last year and this year, they have been lower than historical rates.” — Mark L. Hair, Chief Financial Officer · 2026-11-06 That is the same soft-market language Treace used in prior calls, and it is why the company will not guide 2027 until it sees Q4 case volumes and a few more months of new-product experience. The stock's reaction tells you the market wanted more than a narrowed guide. TMCI is down about 20% from its October 29 peak, even after a Q3 beat, and the full-history tape still shows an 84% decline from its 2021 high. The company does not need to prove that surgeons like the products; it needs to prove that ankle procedures and the broader portfolio can turn double-digit procedure growth into positive revenue growth. Until then, the transition remains a promise with a P&L to match.